Fran Williams speaks to Sanne van der Burgh and Jaka Korla of MVRDV NEXT about their use of digital technology to push the ...

Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...